Company Overview and News

4
BeiGene Reports Second Quarter 2018 Financial Results

2018-08-09 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018.
CICHY CELGZ MRTX CELG BGNE CICHF CCB 0939

0
Global Growth Continues but with Higher Uncertainty - Dallasfed.org

2018-08-07 dallasfed.org
The Federal Reserve Bank of Dallas established the Globalization Institute in 2007 for the purpose of better understanding how the process of deepening economic integration between the countries of the world, or globalization, alters the environment in which U.S. monetary policy decisions are made.
CICHY 55BC CBQS CICHF CCB 0939

1
Principal Financial Group, Inc. (PFG) CEO Daniel Houston on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Principal Financial Group, Inc. (NYSE:PFG) Q2 2018 Earnings Conference Call July 27, 2018 10:00 AM ET
CICHY PFG IG CICHF CCB 0939

0
China’s easing move draws value hunters to unloved bank stocks

2018-07-27 malaymail
HONG KONG, July 27 — Value hunters are paying more attention to China’s unloved banking stocks after the government softened its deleveraging drive.
CICHY 55BC CBQS CICHF CCB 0939

0
China's Easing Move Draws Value Hunters to Unloved Bank Stocks - Bloomberg

2018-07-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CICHY 55BC CBQS CICHF CCB 0939

7
Private capital still pinching tech IPOs globally

2018-07-23 theedgemarkets
KUALA LUMPUR: Over the past couple of years, stock exchanges around the world have been busy creating and amending regulations to make initial public offerings (IPOs) an attractive means of fundraising for technology companies looking to raise capital.
FB GOOG SFTBF CBQS S68 HSB AAPL CICHF HSBC CCB SFTBY 0939 HBCYF SPXCF 55BC HCS CICHY 0005 SPXCY GOOGL HSEA HSEB MSFT 9984 BSMAF 1818

0
China’s local govts plan more EV makers

2018-07-20 thestar.com.my
OFFICIALS in the old mining town of Tongling, China, knew almost nothing about electric vehicles (EVs) when they gave a startup US$535mil in land and capital to build an electric-car plant there two years ago.
CICHY CICHF CCB 0939

0
The absurdity of Navarro’s Death by China - Global Times

2018-07-16 globaltimes.cn
Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, is President Donald Trump's stalking horse in a potentially open-ended trade war with China. Armed with a Harvard Ph.D. and academic tenure from the University of California (Irvine), a well-credentialed Navarro was in the right place at the right time to make the leap into the political arena and orchestrate America's increasingly aggressive China bashing strategy.
CICHY MS CICHF CCB 0939

0
Large global investor says its portfolio grew to a record size, but it may slow down investments

2018-07-10 cnbc
Singapore’s state investment firm Temasek Holdings said Tuesday the value of its portfolio jumped above 300 billion Singapore dollars for the first time ever.
CICHY 55BC CBQS CICHF CCB 0939

0
Singapore's Temasek sees slower investments after record portfolio

2018-07-10 malaymail
SINGAPORE, July 10 — Singapore state investor Temasek Holdings' portfolio value hit a record high last year on strong performance in local firms and Chinese banks, but it struck a cautious note by saying it was looking to temper the pace of its investments.
STAN 55BC CBQS CICHY 580001 STAB STAN STAC 2888 SCBFF CICHF CCB 0939

0
Singapore's Temasek sees deals slowing as trade tensions bite

2018-07-10 theedgemarkets
SINGAPORE (July 10): Singapore state investor Temasek Holdings cautioned it was looking to temper its pace of investments this year as trade tensions between world's top two economies ratchet up, after reporting a record high annual portfolio value.
CICHY CICHF CCB 0939

1
China sovereign fund CIC profit soars on record overseas returns

2018-07-09 reuters
SHANGHAI/BEIJING (Reuters) - China’s sovereign wealth fund China Investment Corp (CIC) posted a 37.55 percent rise in 2017 net profit, boosted by record-high returns from its overseas portfolio.
CICHY 55BC TCKRF CBQS CICHF CCB TECK 0939

0
RPT-Singapore's Temasek set to report record portfolio; tech deals in focus

2018-07-08 reuters
SINGAPORE, July 8 (Reuters) - Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion ($221 billion) for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Singapore's Temasek set to report record portfolio; tech deals in focus

2018-07-08 theedgemarkets
SINGAPORE (July 8): Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Singapore’s Temasek set to report record portfolio; tech deals in focus

2018-07-08 malaymail
SINGAPORE, July 8 — Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion (RM892.7 billion) for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...